MM-D37K: Phase I/IIa started

MetaMax began a Russian Phase I/IIa trial to evaluate MM-D37K in 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors. MetaMax is a portfolio company of Max...